Cargando…
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
Here we present the 3-year results of ZUMA-4, a phase I/II multicenter study evaluating the safety and efficacy of KTEX19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in pediatric/adolescent patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Phase I ex...
Autores principales: | Wayne, Alan S., Huynh, Van, Hijiya, Nobuko, Rouce, Rayne H., Brown, Patrick A., Krueger, Joerg, Kitko, Carrie L., Dela Ziga, Edward, Hermiston, Michelle L., Richards, Michael K., Baruchel, Andre, Schuberth, Petra C., Rossi, John, Zhou, Lang, Goyal, Lovely, Jain, Rajul, Vezan, Remus, Masouleh, Behzad Kharabi, Lee, Daniel W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973494/ https://www.ncbi.nlm.nih.gov/pubmed/36263840 http://dx.doi.org/10.3324/haematol.2022.280678 |
Ejemplares similares
-
CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022) -
CLL-050 Induction of Neutralizing Antibodies in Chronic Lymphocytic Leukemia Patients After SARS-CoV-2 mRNA Vaccination: A Monocentric Experience
por: Mavilia, Fabrizio, et al.
Publicado: (2022) -
CLL-224 Coronavirus Disease Mortality and Outcome in Macedonian Patients With Chronic Lymphocytic Leukemia: Single-Center Experience
por: Trajkova, Sanja, et al.
Publicado: (2022) -
ALL-083 ALLogeneic Hematopoietic Stem Cell Transplantation of a R/R T-ALL Patient Given Nelarabine, 3 Weeks Post Moderate COVID-19 Infection in the Local Setting
por: Uong, Flaryll
Publicado: (2022) -
CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study
por: St-Pierre, Frédérique, et al.
Publicado: (2022)